Search
CareDx Inc
CDNAAdd to Watchlist
28.570USD
-0.680-2.32%
Market hours （ET）Quotes delayed by 15 min
1.47BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.32%
5 Days
+5.31%
1 Month
+25.31%
6 Months
+51.65%
Year to Date
+51.65%
1 Year
+51.56%
Key Figures
29.820Open
30.000High
170.85KVolume
LossP/E TTM
28.67P/E Dynamic
--Dividend TTM
0.33%Turnover Ratio
29.250Prev. Close
28.500Low
3.38MTurnover
27.95P/E Static
4.72P/B
0.00%Div Yield TTM
-1.82%ROA
23.24052wk High
0.90Volume Ratio
52.55MNet Profit
51.41MShares
-0.1585EPS TTM
2.49Beta
-2.36%ROE
10.96052wk Low
5.13%Amplitude
71.43%Gross Margin
1.47BMarket Cap
8.38Reward/Risk
3.88%Risk Rate
TradingKey Stock Score of CareDx Inc
Currency: USD Updated: 2026-07-01Key Insights
CareDx Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 8 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.80.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CareDx Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
CareDx Inc Highlights
StrengthsRisks
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.49% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -184.57, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 52.46M shares, decreasing 15.72% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 1.75M shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
25.800
Target Price
-9.47%
Upside Space
CareDx Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CareDx Inc Info
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
Ticker SymbolCDNA
CompanyCareDx Inc
CEOHanna (John W)
Websitehttps://www.caredx.com/
Related Instruments
+2.31%
+1.41%
+4.86%
+2.00%
+1.93%
+3.35%
+2.55%
+3.66%
+2.81%
+1.95%
+3.94%
+1.79%
+3.70%
+3.36%
+1.41%
0.00%
+2.45%
+3.92%
+0.58%
+4.20%Popular Instruments
52719.900
+465.600 (+0.89%)
29689.700
-109.600 (-0.37%)
7512.200
+36.700 (+0.49%)
14840.000
-515.000 (-3.35%)
68864.000
-621.000 (-0.89%)
6373.000
+97.600 (+1.55%)
67.584
-0.384 (-0.56%)
304.670
+10.290 (+3.50%)
198.779
+1.199 (+0.61%)
4118.100
+87.330 (+2.17%)
FAQs
What is the current price of CareDx Inc (CDNA)?
The current price of CareDx Inc (CDNA) is 29.25.
What is the symbol of CareDx Inc?
The ticker symbol of CareDx Inc is CDNA.
What is the 52-week high of CareDx Inc?
The 52-week high of CareDx Inc is 23.24.
What is the 52-week low of CareDx Inc?
The 52-week low of CareDx Inc is 10.96.
What is the market capitalization of CareDx Inc?
The market capitalization of CareDx Inc is 1.51B.
Is CareDx Inc (CDNA) currently rated as Buy, Hold, or Sell?
According to analysts, CareDx Inc (CDNA) has an overall rating of Buy, with a price target of 25.80.
What is the Earnings Per Share (EPS TTM) of CareDx Inc (CDNA)?
The Earnings Per Share (EPS TTM) of CareDx Inc (CDNA) is -0.40.